Gastrointestinal Neuroendocrine Carcinoma Clinical Trials in Beijing, Beijing Municipality

First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma